Xceleron, the bioanalytical CRO, which has pioneered human Phase 0 microdose studies, today announced the appointment of Professor Malcolm Rowland as Chairman to the Company’s newly formed Scientific Advisory Board. Malcolm Rowland is Professor Emeritus and former Dean at the School of Pharmacy and Pharmaceutical Sciences and member of the Centre for Applied Pharmacokinetic Research at the University of Manchester, UK.
